{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:21:05Z","timestamp":1790742065462,"version":"4.1.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,7,5]],"date-time":"2018-07-05T00:00:00Z","timestamp":1530748800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.clml.2018.06.016","type":"journal-article","created":{"date-parts":[[2018,6,28]],"date-time":"2018-06-28T06:30:15Z","timestamp":1530167415000},"page":"648-657.e15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":76,"title":["Safety Analysis of Four Randomized Controlled\u00a0Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma"],"prefix":"10.1016","volume":"18","author":[{"given":"Susan","family":"O'Brien","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5617-4403","authenticated-orcid":false,"given":"Peter","family":"Hillmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Coutre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9733-401X","authenticated-orcid":false,"given":"Paul M.","family":"Barr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graeme","family":"Fraser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Tedeschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan A.","family":"Burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Sarah","family":"Dilhuydy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Hess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Cramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Vermeulen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori","family":"Styles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Howes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danelle F.","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalpesh","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"Graef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolph","family":"Valentino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2018.06.016_bib1","series-title":"IMBRUVICA\u00ae (ibrutinib) prescribing information","year":"2018"},{"key":"10.1016\/j.clml.2018.06.016_bib2","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2018.06.016_bib3","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2018.06.016_bib4","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S1470-2045(15)00465-9","article-title":"Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study","volume":"17","author":"Chanan-Khan","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2018.06.016_bib5","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S0140-6736(15)00667-4","article-title":"Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study","volume":"387","author":"Dreyling","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2018.06.016_bib6","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.06.016_bib7","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1182\/blood-2016-06-722991","article-title":"Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib","volume":"128","author":"Ahn","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.06.016_bib8","first-page":"1","article-title":"Disseminated cryptococcal disease in a patient with chronic lymphocytic leukemia on ibrutinib","volume":"2016","author":"Okamoto","year":"2016","journal-title":"Case Rep Infect Dis"},{"key":"10.1016\/j.clml.2018.06.016_bib9","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/hon.2387","article-title":"Severe pneumonia associated with ibrutinib monotherapy for CLL and lymphoma","volume":"36","author":"Kreiniz","year":"2018","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2018.06.016_bib10","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.jacc.2013.11.026","article-title":"Insights into onco-cardiology: atrial fibrillation in cancer","volume":"63","author":"Farmakis","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.clml.2018.06.016_bib11","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s11739-011-0701-9","article-title":"Colorectal cancer and risk of atrial fibrillation and flutter: a population-based case-control study","volume":"7","author":"Erichsen","year":"2012","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.clml.2018.06.016_bib12","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1080\/10428194.2016.1257795","article-title":"Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL)","volume":"58","author":"Shanafelt","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2018.06.016_bib13","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/bjh.14324","article-title":"Atrial fibrillation in CLL patients treated with ibrutinib: an international retrospective study","volume":"175","author":"Thompson","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2018.06.016_bib14","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.3324\/haematol.2017.171041","article-title":"Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials","volume":"102","author":"Brown","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2018.06.016_bib15","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/10428190701724785","article-title":"Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia","volume":"49","author":"Thurmes","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2018.06.016_bib16","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1750-1172-8-32","article-title":"Cost of illness and economic burden of chronic lymphocytic leukemia","volume":"8","author":"Blankart","year":"2013","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.clml.2018.06.016_bib17","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1365-2141.2007.06791.x","article-title":"Quality of life in chronic lymphocytic leukemia: an international survey of 1482 patients","volume":"139","author":"Shanafelt","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2018.06.016_bib18","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/blood.V126.23.3268.3268","article-title":"Incidence of major hemorrhage among CLL and MCL patients compared to the general elderly population: an analysis of the US SEER-Medicare linked database","volume":"126","author":"Gifkins","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.06.016_bib19","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/bjh.14660","article-title":"Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib","volume":"178","author":"Jones","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2018.06.016_bib20","first-page":"1743","article-title":"Incidence of and risk factors for major hemorrhage in patients treated with ibrutinib: results from an integrated analysis","volume":"130","author":"Brown","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.06.016_bib21","first-page":"238","article-title":"A\u00a0simple method for estimating confidence intervals for exposure adjusted incidence rate and its applications to clinical trials","volume":"6","author":"He","year":"2015","journal-title":"J\u00a0Biom Biostat"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265018302659?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265018302659?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:32:10Z","timestamp":1761870730000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265018302659"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":21,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S2152265018302659"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2018.06.016","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety Analysis of Four Randomized Controlled\u00a0Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2018.06.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}